PHAGOCYTIC ACTIVITY OF NEUTRHOPHILS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND LUNG INJURY
V. Hayevska, V. Hayevskyy, O. Kovalyshyn
Lviv National Medical University named by Danylo
We evaluated spontaneous phagocytic activity of monocytes
and the reserved capacity of neutrophils in patients with
systemic sclerosis with pulmonary injury of various kinds:
pneumofibrosis and pulmonary hypertension. We found
that among patients with systemic sclerosis, lung injury was
observed in 71.6%, including 52.8% with pneumofibrosis,
11.4% with pulmonary hypertension and 35.8% with a combination
of these pathologies. Analysis of phagocytic system
in the groups of patients showed: an increased spontaneous
neutrophil phagocytic activity in patients with systemic sclerosis
and lung damage, which is 33.3% higher as compared to
patients with systemic sclerosis without lung damage. These
changes are more pronounced in patients with a combination
of pneumofibrosis and pulmonary hypertension (P <0.001).
At the same time, reducing the backup of phagocytic ability
of monocytes were found in patients with systemic sclerosis
and pneumofibrosis, which is 37.8% lower as compared with
patients with combination of pneumofibrosis and pulmonary
hypertension, and 21.1% lower in patients with pulmonary
hypertension. Thus, studies of phagocytosis of neutrophils
and monocytes gave us the opportunity to identify groups of
patients with systemic sclerosis without damaging the lungs to
group of the patients with initial changes in lung tissue, later
verified by computer tomography (19.1%).
systemic sclerosis; lung damage; phagocytosis.
- Poormoghim H. Systemic sclerosis: demographic, clinical and serological features in patients. Rheumatol Int. 2013; 33: 1943–50.
- Tamby M, Chanseaud Y, Guillevin L, et al. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev. 2003; 2: 152–157.
- Gutsche M, Rosen D, Swigris J. Connective tissue diseaseassociated interstitial lung disease: a review. Curr Respir Care Rep. 2013; 1(21): 224–232.
- Dooley A. Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. Cardiol Res Pract. 2012; 33: 1155–62.
- Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007; 66(38): 940–944.
- Dovzhansky S. Clinical and immunological parallels with limited systemic scleroderma. Cutaneous and Ven Bol. 2009; 25: 26–29 [Ukrainian].
- Dumit V, Küttner V, Käppler J, Piera-Velazquez S, et al Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2014; 18, 134:2321–30.
- Kuwana M. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2012; 23: 258–63.
- McNearney T, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007; 57(45): 318–26.
- De Lauretis A, Veeraraghavan S, Renzoni E. Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011; 8: 53–82.
- Castello-Cros R, Whitaker-Menezes D, Molchansky A. Scleroderma-like properties of skin from caveolin-1- deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle. 2011; 32 (10): 2140–50.
- Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine sclerodermaassociated interstitial lung disease. Chest J. 2006; 30 (130): 976–81.
- Czirjak L. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2013; 71: 1355-60.
- Bukhari SN, Tajuddin Y, Benedict VJ Synthesis and evaluation of chalcone derivatives as inhibitors of neutrophils' chemotaxis, phagocytosis and production of reactive oxygen species. Chem Biol Drug Des. 2014; 83(2):198-206.
- Solomon J, Amy L, Aryeh F. Scleroderma lung disease. Eur Respir Rev. 2013; 1: 6–19.
- Sanchez V, Hansmannb G, Klepetkoc A. ESC/ERS pulmonary injury guidelines and connective tissue disease. Allergol Int. 2011; 60(4): 419–24.
- Rockall AG, Rickards PJ. Imaging of the pulmonary manifestations of systemic disease. Postgrad Med J. 2001; 34: 621–38.
- Highland KB, Garin MC, Brown KK. The spectrum of scleroderma lung disease. Semin Respir Crit Care Med. 2007; 48: 418–29.
- Wite M. Pulmonary blood volume indexed to lung volume is reduced in newly diagnosed systemic sclerosis compared to normals - a prospective clinical cardiovascular magnetic resonance study addressing pulmonary vascular changes. J Cardiovasc Magn Reson. 2013; 25: 86–92.
- Wigley F. Vascular disease in scleroderma. Clini Rev Allergy and Immunol. 2009; 36(25): 150–74.